MA18.09 Carboplatin, Etoposide, Bevacizumab, and Atezolizumab in Patients with Extensive-Stage SCLC - GOIRC-01-2019 CeLEBrATE Trial

The addition of programmed-death ligand 1 (PD-L1) inhibition to platinum-etoposide improved survival in extensive stage small-cell lung cancer (ES-SCLC). Vascular endothelial growth factor (VEGF) has immunosuppressive effects in SCLC tumor micro-environment. We have previously demonstrated safety and signals of activity of adding bevacizumab, an anti-VEGF monoclonal antibody, to platinum-etoposide chemotherapy in the phase III FARM6PMFJM trial. Because combining PD-L1 and VEGF inhibition has synergistic antitumor effect in SCLC models, we hypothesized that adding bevacizumab to atezolizumab, carboplatin and etoposide would improve survival in patients with ES-SCLC.